In most hospitals, newborn babies are screened for a variety of metabolic disorders, including medium-chain acyl-CoA dehydrogenase deficiency (MCADD). This screening process uses high-performance liquid chromatography (HPLC) to determine the acylcarnitine profile in the bloodstream. In newborns with MCADD, which acylcarnitine is elevated?